Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
63
MRUS Quote, Financials, Valuation and Earnings
Last price:
$96.92
Seasonality move
:
11.04%
Day range:
$96.91 - $96.96
52-week range:
$33.19 - $97.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
121.82x
P/B ratio:
9.48x
Volume:
193.8K
Avg. volume:
1.2M
1-year change:
128.51%
Market cap:
$7.4B
Revenue:
$36.1M
EPS (TTM):
-$5.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$8.7M | -$1.36 | -7.07% | -135.86% | $97.00 |
|
ARGX
argenx SE
|
$1.1B | $4.11 | 87.13% | 205.62% | $1,010.28 |
|
GMAB
Genmab A/S
|
$987.6M | $0.45 | 11.78% | -50.53% | $37.81 |
|
PHAR
Pharming Group NV
|
$91.2M | $0.00 | 11.23% | -90.74% | $31.00 |
|
PRQR
ProQR Therapeutics NV
|
$7M | -$0.17 | 32.53% | -55.96% | $8.88 |
|
QURE
uniQure NV
|
$5.2M | -$0.86 | 8.51% | -38.17% | $55.30 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$96.91 | $97.00 | $7.4B | -- | $0.00 | 0% | 121.82x |
|
ARGX
argenx SE
|
$848.48 | $1,010.28 | $52.2B | 43.13x | $0.00 | 0% | 18.10x |
|
GMAB
Genmab A/S
|
$33.72 | $37.81 | $20.7B | 14.32x | $0.00 | 0% | 5.90x |
|
PHAR
Pharming Group NV
|
$18.09 | $31.00 | $1.2B | 1,265.04x | $0.00 | 0% | 3.41x |
|
PRQR
ProQR Therapeutics NV
|
$2.17 | $8.88 | $228.6M | -- | $0.00 | 0% | 13.13x |
|
QURE
uniQure NV
|
$25.19 | $55.30 | $1.6B | -- | $0.00 | 0% | 86.07x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MRUS
Merus NV
|
1.57% | 2.127 | 0.17% | 7.55x |
|
ARGX
argenx SE
|
-- | 0.059 | -- | 4.92x |
|
GMAB
Genmab A/S
|
2.41% | 0.687 | 0.75% | 6.01x |
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.523 | 7.64% | 3.23x |
|
QURE
uniQure NV
|
69.92% | 0.547 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MRUS
Merus NV
|
$11.5M | -$96.5M | -52.67% | -53.47% | -794.06% | -$90.4M |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
GMAB
Genmab A/S
|
$959.7M | $457M | 27.54% | 28.3% | 44.91% | $535M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
Merus NV vs. Competitors
-
Which has Higher Returns MRUS or ARGX?
argenx SE has a net margin of -786.17% compared to Merus NV's net margin of 25.88%. Merus NV's return on equity of -53.47% beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV94.71% -$1.26 $787.2M ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About MRUS or ARGX?
Merus NV has a consensus price target of $97.00, signalling upside risk potential of 0.09%. On the other hand argenx SE has an analysts' consensus of $1,010.28 which suggests that it could grow by 19.38%. Given that argenx SE has higher upside potential than Merus NV, analysts believe argenx SE is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV2 13 0 ARGXargenx SE15 2 0 -
Is MRUS or ARGX More Risky?
Merus NV has a beta of 1.061, which suggesting that the stock is 6.069% more volatile than S&P 500. In comparison argenx SE has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.397%.
-
Which is a Better Dividend Stock MRUS or ARGX?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or ARGX?
Merus NV quarterly revenues are $12.2M, which are smaller than argenx SE quarterly revenues of $948M. Merus NV's net income of -$95.5M is lower than argenx SE's net income of $245.4M. Notably, Merus NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 43.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 121.82x versus 18.10x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV121.82x -- $12.2M -$95.5M ARGXargenx SE18.10x 43.13x $948M $245.4M
-
Which has Higher Returns MRUS or GMAB?
Genmab A/S has a net margin of -786.17% compared to Merus NV's net margin of 39.24%. Merus NV's return on equity of -53.47% beat Genmab A/S's return on equity of 28.3%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV94.71% -$1.26 $787.2M GMABGenmab A/S94.33% $0.64 $5.9B -
What do Analysts Say About MRUS or GMAB?
Merus NV has a consensus price target of $97.00, signalling upside risk potential of 0.09%. On the other hand Genmab A/S has an analysts' consensus of $37.81 which suggests that it could grow by 12.14%. Given that Genmab A/S has higher upside potential than Merus NV, analysts believe Genmab A/S is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV2 13 0 GMABGenmab A/S6 2 0 -
Is MRUS or GMAB More Risky?
Merus NV has a beta of 1.061, which suggesting that the stock is 6.069% more volatile than S&P 500. In comparison Genmab A/S has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.809%.
-
Which is a Better Dividend Stock MRUS or GMAB?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Genmab A/S pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or GMAB?
Merus NV quarterly revenues are $12.2M, which are smaller than Genmab A/S quarterly revenues of $1B. Merus NV's net income of -$95.5M is lower than Genmab A/S's net income of $399.2M. Notably, Merus NV's price-to-earnings ratio is -- while Genmab A/S's PE ratio is 14.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 121.82x versus 5.90x for Genmab A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV121.82x -- $12.2M -$95.5M GMABGenmab A/S5.90x 14.32x $1B $399.2M
-
Which has Higher Returns MRUS or PHAR?
Pharming Group NV has a net margin of -786.17% compared to Merus NV's net margin of 7.71%. Merus NV's return on equity of -53.47% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV94.71% -$1.26 $787.2M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About MRUS or PHAR?
Merus NV has a consensus price target of $97.00, signalling upside risk potential of 0.09%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 71.37%. Given that Pharming Group NV has higher upside potential than Merus NV, analysts believe Pharming Group NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV2 13 0 PHARPharming Group NV2 0 0 -
Is MRUS or PHAR More Risky?
Merus NV has a beta of 1.061, which suggesting that the stock is 6.069% more volatile than S&P 500. In comparison Pharming Group NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MRUS or PHAR?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PHAR?
Merus NV quarterly revenues are $12.2M, which are smaller than Pharming Group NV quarterly revenues of $96.9M. Merus NV's net income of -$95.5M is lower than Pharming Group NV's net income of $7.5M. Notably, Merus NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,265.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 121.82x versus 3.41x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV121.82x -- $12.2M -$95.5M PHARPharming Group NV3.41x 1,265.04x $96.9M $7.5M
-
Which has Higher Returns MRUS or PRQR?
ProQR Therapeutics NV has a net margin of -786.17% compared to Merus NV's net margin of -381.88%. Merus NV's return on equity of -53.47% beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV94.71% -$1.26 $787.2M PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About MRUS or PRQR?
Merus NV has a consensus price target of $97.00, signalling upside risk potential of 0.09%. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 308.99%. Given that ProQR Therapeutics NV has higher upside potential than Merus NV, analysts believe ProQR Therapeutics NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV2 13 0 PRQRProQR Therapeutics NV7 0 0 -
Is MRUS or PRQR More Risky?
Merus NV has a beta of 1.061, which suggesting that the stock is 6.069% more volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.176, suggesting its less volatile than the S&P 500 by 82.397%.
-
Which is a Better Dividend Stock MRUS or PRQR?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or PRQR?
Merus NV quarterly revenues are $12.2M, which are larger than ProQR Therapeutics NV quarterly revenues of $3.4M. Merus NV's net income of -$95.5M is lower than ProQR Therapeutics NV's net income of -$12.9M. Notably, Merus NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 121.82x versus 13.13x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV121.82x -- $12.2M -$95.5M PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M
-
Which has Higher Returns MRUS or QURE?
uniQure NV has a net margin of -786.17% compared to Merus NV's net margin of -2175.87%. Merus NV's return on equity of -53.47% beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital MRUSMerus NV94.71% -$1.26 $787.2M QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About MRUS or QURE?
Merus NV has a consensus price target of $97.00, signalling upside risk potential of 0.09%. On the other hand uniQure NV has an analysts' consensus of $55.30 which suggests that it could grow by 119.54%. Given that uniQure NV has higher upside potential than Merus NV, analysts believe uniQure NV is more attractive than Merus NV.
Company Buy Ratings Hold Ratings Sell Ratings MRUSMerus NV2 13 0 QUREuniQure NV9 2 0 -
Is MRUS or QURE More Risky?
Merus NV has a beta of 1.061, which suggesting that the stock is 6.069% more volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.
-
Which is a Better Dividend Stock MRUS or QURE?
Merus NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merus NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MRUS or QURE?
Merus NV quarterly revenues are $12.2M, which are larger than uniQure NV quarterly revenues of $3.7M. Merus NV's net income of -$95.5M is lower than uniQure NV's net income of -$80.5M. Notably, Merus NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merus NV is 121.82x versus 86.07x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MRUSMerus NV121.82x -- $12.2M -$95.5M QUREuniQure NV86.07x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
